Allspring Global Investments
RNAC icon

Allspring Global Investments’s Cartesian Therapeutics RNAC Stock Holding History

Allspring Global Investments’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-1,597
Closed -$50.8K – 2651
2023
Q3 		$50.8K Buy
+1,597
New +$53.3K ﹤0.01% 2269
2022
Q2 		– Sell
-5,543
Closed -$204K – 2890
2022
Q1 		$204K Buy
5,543
+875
+19% +$54.7K ﹤0.01% 2564
2021
Q4 		$456K Buy
+4,668
New +$502K ﹤0.01% 2332

Other funds holding RNAC

AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Allspring Global Investments's RNAC Position: Q4 2023 in Review

Allspring Global Investments sold out of Cartesian Therapeutics (RNAC) in Q4 2023, closing a stake of 1,597 shares — an estimated $50.8K sold.

Allspring Global Investments first reported a position in RNAC in Q4 2021 and held it in 3 quarters. The position peaked at $456K in Q4 2021. 80 funds tracked by Wall St. Rank hold RNAC as of Q4 2023.

  • Allspring Global Investments reported no remaining Cartesian Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Allspring Global Investments sold 1,597 Cartesian Therapeutics shares in Q4 2023, an estimated $50.8K.
  • Allspring Global Investments first reported a position in Cartesian Therapeutics in Q4 2021 and held it in 3 quarters.
  • Allspring Global Investments's Cartesian Therapeutics position peaked at $456K in Q4 2021.
  • 80 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q4 2023.

Based on Allspring Global Investments's 13F filing for Q4 2023, filed 25 Jan 2024.